@taneuroldisord.bsky.social
A leading gold #OpenAccess journal in clinical neurology | IF 4.1 CiteScore 8.5 | π§ Follow us for neurological research and news.
Is increased middle cerebral artery peak systolic velocity associated with the development of malignant media infarction after endovascular thrombectomy?
Find out more in this study, recently published in Therapeutic Advances in Neurological Disorders: #stroke
journals.sagepub.com/doi/full/10....
A new RCT online!
Lisa SchΓ€fer and colleagues show how multidisciplinary online care can improve mental health, vitality, and quality of life in women with X-linked adrenoleukodystrophy - a model that could be scaled for other rare disorders.
#RareDisease
journals.sagepub.com/doi/pdf/10.1...
New study by Matteo Foschi et al reveals sex-specific patterns in #MultipleSclerosis progression:
Womenβespecially postmenopausalβface higher risk of disability worsening independent of relapses, while men experience greater impact per event:
journals.sagepub.com/doi/full/10....
New Review online!
Here, Joost Smolders and colleagues argue that aggressive treatment of early acute focal inflammatory activity in #MultipleSclerosis can extend the window for BTK inhibition and slow down progression
journals.sagepub.com/doi/full/10....
New Review online!
Here, Wolfgang Jost and Jiri Koschel discuss approaches for diagnosing and treating cardiovascular symptoms in #Parkinsonβs disease:
journals.sagepub.com/doi/full/10....
π§ 20 years of #natalizumab in #MultipleSclerosis care:
A new Review reflects on two decades of clinical experience with natalizumabβits efficacy, safety, and evolving role in treatment strategies.
π Read this Open Access article here: doi.org/10.1177/1756...
Elevated liver enzymes (AST, ALT, GGT) may correlate with lower #migraine prevalenceβespecially migraines without aura.
Could glutamate regulation be a metabolic clue in migraine pathology?
New study by Angela Ruban and colleagues:
journals.sagepub.com/doi/full/10....
Could GLP-1 receptor agonists affect Parkinsonβs disease progression?
Check out this recent meta-analysis by Tsai et al:
journals.sagepub.com/doi/full/10....
Which imaging and soluble #biomarkers best predict progression from relapsing-remitting #MultipleSclerosis to secondary progressive MS?
Sini Laaksonen & colleagues investigate: journals.sagepub.com/doi/full/10....
In #ALS, analysis of 636 patients (2013β2023) found racial and ethnic disparities in care: Non-Hispanic Black patients had higher tracheostomy rates, and Hispanic patients were less likely to receive riluzole. Survival was similar across groups.
π journals.sagepub.com/doi/epdf/10....
In rescue stenting after failed thrombectomy, dual antiplatelet therapy post-procedure improved outcomes and reduced mortality and stent occlusion vs single therapy. Most occlusions occurred within 24βh, underscoring early management importance.
π journals.sagepub.com/doi/epdf/10....
In #ParkinsonsDisease, orthostatic hypotension (OH) is a disabling feature linked to poor quality of life and fall risk. This review summarizes pharmacologic and nonpharmacologic strategies for managing OH in PD.
π journals.sagepub.com/doi/epdf/10....
Case series: #Levodopaβcarbidopa intestinal gel (LCIG) reduced βoffβ time & dyskinesia in young-onset #MSA-P patients with preserved levodopa response. While ADLs declined with progression, LCIG may offer benefit for selected cases.
journals.sagepub.com/doi/epdf/10....
π§ͺ Long-term study of #Cladribine in #MultipleSclerosis shows no loss of humoral immunity after up to 7 years. Patients maintained protective IgG to common pathogens & mounted new responses (e.g. SARS-CoV-2). Supports strong long-term safety profile.
journals.sagepub.com/doi/epdf/10....
New national guidelines for #MyastheniaGravis in Israel standardize diagnosis & treatment. They integrate antibody testing, imaging, thymectomy recommendations, & tailored immunotherapy to improve outcomes & reduce care disparities.
journals.sagepub.com/doi/epdf/10....
Review: immune tolerance in #NMOSD/#MOGAD as an alternative to long-term immunosuppression. Strategies include antigen-specific vaccines/nanoparticles, Treg/Breg cell therapy, and gene editing. Aim: durable remission with fewer systemic effects.
journals.sagepub.com/doi/epdf/10....
Phase IV MAGNIFY-MS (n=270) in relapsing #MS: cladribine tablets achieved 64% NEDA-3 and 60% NEPAD at 2 years; ARR 0.09 (0.04 Tx-naΓ―ve). Biomarkers improved with OCB reduction in 76%, lower KFLC and IgG indices, sustained NfL decline, and no OCT thinning.
journals.sagepub.com/doi/epdf/10....
Cross-sectional study in #MultipleSclerosis (n=80): serum GFAP was higher in progressive MS & correlated with TSPO-PET activity, lesion load, and reduced brain volumes. Findings support sGFAP as a biomarker of astrocyte-driven pathology and MS progression
journals.sagepub.com/doi/epdf/10....
Narrative review on neuropsychiatric disorders in #Parkinsons highlights depression, anxiety, apathy, hallucinations & impulse control disorders as common features. Early detection & tailored multidisciplinary care are essential to improve QoL.
Read here: journals.sagepub.com/doi/epdf/10....
Prospective study in branch atheromatous disease (#stroke subtype): early intensive therapy with dual antiplatelets + high-intensity statins reduced early neuro deterioration (34.1% vs 48.1%) & improved 90-day outcomes, with no β in major bleeding.
Read: journals.sagepub.com/doi/epdf/10....
Study in #NMOSD (AQP4-IgG+) & #MOGAD: higher serum GFAP, but not NfL, was linked to lower hippocampal & thalamic volumes and β CSF volume on MRI. Findings support sGFAP as a biomarker of disease activity in AQP4-IgG+NMOSD.
Read here: journals.sagepub.com/doi/epdf/10....
New online:
READAPT multicenter: #DAPT in mildβmoderate ischemic #stroke; anterior vs posterior infarcts (n=932; propensity matched). 90-day recurrent events similar (3.1% vs 2.9%); safety comparable. Posterior infarcts had worse 90-day mRS.
Read here: journals.sagepub.com/doi/epdf/10....
π In a 13-year real-world study of 3850 MS/NMOSD DMT courses, 24.2% were stopped due to AEs. Just 1.7% were atypical, 3.1% unusually severeβspotlighting rare but impactful safety signals.
π journals.sagepub.com/doi/epdf/10....
#NeuroTwitter #MS #NMOSD
πΉ Telitacicept in refractory gMG: In this real-world cohort (n=16), 90% showed symptomatic improvement at 6 months. MG-ADL, QMG, & steroid burden all improved, with no severe AEs reported.
A feasible new add-on for treatment-resistant cases.
π doi.org/10.1177/1756...
πΉ Zilucoplan in AChR+ gMG: Long-term data from the RAISE-XT OLE study (n=200) showed sustained efficacy through Week 60, with continued MG-ADL improvements & no new safety signals.
A promising maintenance option for patients with mildβsevere disease.
π doi.org/10.1177/1756...
Yesterday was #MyalgicEncephalomyelitis & #ChronicIllness Awareness Day
In honour of those living with chronic immunological + neurological conditions, weβre spotlighting new research on generalized myasthenia gravis from Therapeutic Advances in Neurological Disorders π§΅π
π‘ In a patient with refractory epilepsy, personalized ANT-DBS settings (125βHz, 50βΞΌs) suppressed theta/alpha activity more than standard clinical settings (145βHz, 90βΞΌs). Gamma suppression in-clinic also linked to >50% seizure reduction over 1 year.
doi.org/10.1177/1756...
π In 14 MuSK-MG patients, efgartigimod reduced MG-ADL scores from 10.1 to 2.2 by week 4 (p=0.001); 93% maintained benefit >8wks, and 71% reached minimal symptom expression by week 12. Lower steroid needs with CD20/tacrolimus combo.
doi.org/10.1177/1756...
π In this US claims study (n=1,568), natalizumab as first-line MS therapy cut relapse rates more than later-line use (ARR: 1.48β0.28 vs 0.92β0.41) and showed greater reductions in hospital stays, ER visits, and outpatient use.
doi.org/10.1177/1756...
π¨ Call for Papers β New Frontiers in Acute Reperfusion Therapies for AIS π§
TAN invites submissions on large core infarcts, tandem occlusions, AI in neuroimaging & more. Help shape the future of stroke care.
ποΈ Deadline: Sept 19, 2025
π journals.sagepub.com/topic/collec...
